Reference:EU EMA/698382/2021 - Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol 2021 5.1: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
Gxplex admin (talk | contribs) m 1 revision imported |
||
| (9 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
{{ | {{ReferenceData | ||
| | |has_document=Document:EU EMA/698382/2021 - Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol 2021 | ||
| | |module=4 | ||
| | |unit=4.1.4 | ||
| | |scope=G | ||
|doc_part=5.1 | |||
|language=EN | |||
|entry_by=Florian Adragna | |||
|contributors= | |||
|tags=TAG-00049-Ser-Ver ++ TAG-00244-Def-ini ++ TAG-00033-Pro-oto ++ TAG-00329-Saf-lne | |||
|tags_display=[[Glossary:TAG-00049-Ser-Ver|Serious breach]], [[Glossary:TAG-00244-Def-ini|Definition]], [[Glossary:TAG-00033-Pro-oto|Protocol]], [[Glossary:TAG-00329-Saf-lne|Safety]] | |||
|comment=Definition of what needs to be reported as serious breach | |||
|content=5.1. What needs to be reported? | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|- | |||
| | |||
| | |||
= | |||
5.1. What needs to be reported? | |||
Any breach of: | Any breach of: | ||
| Line 57: | Line 24: | ||
• The reliability and robustness of the data generated in the clinical trial. | • The reliability and robustness of the data generated in the clinical trial. | ||
is serious and should be notified. | is serious and should be notified. | ||
}} | |||
Latest revision as of 13:50, 16 July 2026
| Document information | |
|---|---|
| Reference | EU EMA/698382/2021
- Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol 2021 |
| Validity area | EU |
| Scope(s) | G |
| Document name | EMA/698382/2021
- Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol |
| Version / Revision | 2021 |
| Status | Current |
| Document type | Official guideline |
| Language(s) | EN |
| Description | EMA/698382/2021
Quality and Safety of Medicines Department Guideline for the notification of serious breaches of Regulation (EU) No 536/2014 or the clinical trial protocol |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 4 — Unit 4.1.4 |
| Scope | G |
| Document part | 5.1 |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Serious breach, Definition, Protocol, Safety |
Content
5.1. What needs to be reported?
Any breach of: • The Regulation (EU) No 536/2014. or • The clinical trial protocol version applicable at the time of the breach. which is likely to affect to a significant degree: • The safety of a trial participant. and/or • The rights of a trial participant. and/or • The reliability and robustness of the data generated in the clinical trial. is serious and should be notified.
